Opinion|Videos|May 2, 2025
Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Panelists discuss how PSMA PET imaging is expected to evolve, enhancing precision in prostate cancer treatment through improved detection and staging. Medical professionals anticipate broader use in therapy guidance, with future advancements addressing gaps in early detection and metastasis, improving treatment strategies.
Advertisement
Video content above is prompted by the following:
- Share final thoughts and future perspectives on PSMA PET imaging and its role in the treatment of prostate cancer.
- How do you anticipate the landscape of PSMA PET imaging evolving in the coming years, and what implications might this have for treatment strategies?
- What are your key takeaways from today’s discussion?
- What are the most significant gaps or unmet needs in prostate cancer treatment, and how might future advancements in imaging technologies help address these challenges?
Advertisement
Related to this article
“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.
An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.
“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.
In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.
The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510(k) supported by the HYDROSPACE trial.
“Cardiovascular assessment should begin when the patient is being selected for treatment, not after the toxicity emerges,” said Faisal Mehmud, MD, MRCP.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
Advertisement
Advertisement
Trending on CancerNetwork
1
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
2
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
3
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
4
Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases
5